A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.

MLA

Deeken, John, et al. “A Phase I Study of Liposomal-Encapsulated Docetaxel (LE-DT) in Patients with Advanced Solid Tumor Malignancies.” Cancer Chemotherapy & Pharmacology, vol. 71, no. 3, Mar. 2013, pp. 627–33. EBSCOhost, https://doi.org/10.1007/s00280-012-2048-y.

APA

Deeken, J., Slack, R., Weiss, G., Ramanathan, R., Pishvaian, M., Hwang, J., Lewandowski, K., Subramaniam, D., He, A., Cotarla, I., Rahman, A., & Marshall, J. (2013). A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemotherapy & Pharmacology, 71(3), 627–633. https://doi.org/10.1007/s00280-012-2048-y

Chicago

Deeken, John, Rebecca Slack, Glen Weiss, Ramesh Ramanathan, Michael Pishvaian, Jimmy Hwang, Karen Lewandowski, et al. 2013. “A Phase I Study of Liposomal-Encapsulated Docetaxel (LE-DT) in Patients with Advanced Solid Tumor Malignancies.” Cancer Chemotherapy & Pharmacology 71 (3): 627–33. doi:10.1007/s00280-012-2048-y.